Tocilizumab in severe COVID-19 - A randomized, double-blind, placebo-controlled trial.

ABSTRACT:

Background

The therapeutic effectiveness of interleukin-6 receptor inhibitor in critically ill hospitalized patients with coronavirus disease 2019 (COVID-19) is uncertain.

Methods

To evaluate the efficacy and safety of the outcome as recovery or death of tocilizumab for severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection, we conducted a randomized, double-blinded, placebo-controlled phase 2 trial in critically ill COVID-19 adult patients. The patients were randomly assigned in a 4:1 ratio to receive standard medical treatment plus the recommended dose of either tocilizumab or the placebo drug. Randomization was stratified. The primary outcome was the recovery or death after administration of tocilizumab or a placebo drug. The secondary outcomes were clinic

SUBMITTER: Malik MI 

PROVIDER: S-EPMC9161690 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature